Eisai Co., Ltd. (ESALY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Eisai Co., Ltd. (ESALY) trades at $61.51 with AI Score 57/100 (Grade B). Eisai Co. , Ltd. is a Japan-based pharmaceutical company focused on neurology, oncology, and global generic medicines. Market cap: $17.6B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for ESALY: ESALY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ESALY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ESALY: 1/3 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Eisai Co., Ltd. (ESALY) Healthcare & Pipeline Overview
Eisai Co., Ltd. is a global pharmaceutical company specializing in neurology and oncology, with a strong focus on innovative drug development and strategic collaborations to address unmet medical needs. The company distinguishes itself through its commitment to patient-centric solutions and expanding its global reach.
What Is the Investment Thesis for ESALY?
Eisai's investment thesis centers on its robust pipeline of neurology and oncology drugs, particularly its Alzheimer's disease treatment, Lecanemab (marketed as Leqembi), developed in collaboration with Biogen. The drug's potential to slow cognitive decline in early-stage Alzheimer's patients represents a significant market opportunity. Key value drivers include the successful commercialization of Leqembi, expansion of its oncology portfolio, and strategic partnerships to enhance its global reach. Risks include regulatory hurdles, competition from other Alzheimer's treatments, and the inherent uncertainty of pharmaceutical drug development. Investors should monitor Leqembi's market uptake and Eisai's ability to execute its pipeline development strategy.
Based on FMP financials and quantitative analysis
ESALY Key Highlights
Eisai focuses on neurology and oncology, with a growing emphasis on Alzheimer's disease treatment.
- Strategic collaboration with Biogen on Lecanemab (Leqembi) for Alzheimer's disease, a potential blockbuster drug.
- Strong presence in Japan, the United States, Europe, and Asia, providing a global commercial footprint.
- Commitment to research and development, with a pipeline of novel drug candidates targeting unmet medical needs.
- Patient-centric approach, prioritizing the well-being of patients and their families.
Who Are ESALY's Competitors?
ESALY is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BIIB Biogen Inc. | $217.35 | -1.90% | $32.1B | 64 |
| LLY Eli Lilly and Company | $1245.69 | -2.71% | $1.17T | 97 |
| NVS Novartis AG | $160.31 | +3.73% | $305B | 57 |
| FPHAX Fidelity Select Pharmaceuticals | $35.95 | -3.00% | $1.29B | 47 |
| ELAT Elanco Animal Health Inc | $21.32 | +1.04% | 50 | |
| AMRT American Mart Corporation | $110.00 | +0.00% | 46 | |
| CORI Corium International, Inc. | $12.68 | +0.00% | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ESALY's Key Strengths?
Strong pipeline of neurology and oncology drugs.
- Collaboration with Biogen on Lecanemab (Leqembi) for Alzheimer's disease.
- Global commercial presence and distribution network.
- Commitment to research and development.
What Are ESALY's Weaknesses?
Reliance on key products and partnerships.
- Exposure to regulatory and pricing pressures.
- Competition from other pharmaceutical companies.
- Dependence on successful clinical trial outcomes.
What Could Drive ESALY Stock Higher?
Regulatory approvals for Lecanemab (Leqembi) in additional markets.
- Clinical trial results for pipeline drug candidates.
- Expansion of commercial partnerships and collaborations.
- Increased market penetration of key products.
What Are the Key Risks for ESALY?
Rich valuation — a P/E of 30.0 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Regulatory rejection of drug candidates.
- Unfavorable clinical trial outcomes.
- Competition from other pharmaceutical companies.
- Pricing pressures and healthcare reforms.
- Product liability claims and litigation.
What Are the Growth Opportunities for ESALY?
- Expansion of Lecanemab (Leqembi) Market Share: Eisai has a significant growth opportunity in expanding the market share of Lecanemab, its Alzheimer's disease treatment developed with Biogen. Successful commercialization and market penetration of Lecanemab could drive substantial revenue growth for Eisai. The timeline for this growth opportunity is ongoing, with continued efforts to secure regulatory approvals and expand access to the drug.
- Development of Novel Oncology Therapies: Eisai can capitalize on its research and development capabilities to develop novel oncology therapies for various cancers. The global oncology market is experiencing rapid growth, driven by advancements in cancer diagnostics and treatments. Eisai's focus on developing targeted therapies and immunotherapies could lead to the discovery of breakthrough treatments and generate significant revenue. The timeline for this growth opportunity is medium-term, with ongoing clinical trials and regulatory submissions expected in the next few years.
- Strategic Partnerships and Acquisitions: Eisai can pursue strategic partnerships and acquisitions to expand its product portfolio and geographic reach. Collaborating with other pharmaceutical companies and biotechnology firms can provide access to innovative technologies and drug candidates. Acquiring companies with complementary products and capabilities can strengthen Eisai's market position and accelerate growth. The timeline for this growth opportunity is ongoing, with potential deals and partnerships emerging as Eisai seeks to enhance its competitive advantage.
- Geographic Expansion in Emerging Markets: Eisai can expand its presence in emerging markets, such as China and India, to tap into the growing demand for healthcare products and services. These markets offer significant growth potential due to their large populations and increasing healthcare spending. Eisai can establish local operations, forge partnerships with local distributors, and adapt its products to meet the specific needs of these markets. The timeline for this growth opportunity is long-term, with gradual expansion and investment in emerging markets over the next decade.
- Advancements in Digital Health and Personalized Medicine: Eisai can leverage digital health technologies and personalized medicine approaches to improve patient outcomes and enhance its product offerings. Digital health solutions, such as remote monitoring devices and telehealth platforms, can enable more effective disease management and patient engagement. Personalized medicine approaches, such as biomarker testing and targeted therapies, can tailor treatments to individual patient characteristics. The timeline for this growth opportunity is medium-term, with increasing adoption of digital health technologies and personalized medicine approaches in the healthcare industry.
What Threats Does ESALY Face?
- Regulatory setbacks and delays.
- Patent expirations and generic competition.
- Adverse clinical trial results.
- Economic downturns and healthcare reforms.
What Are ESALY's Competitive Advantages?
- Strong intellectual property protection for its drug products.
- Established brand reputation and relationships with healthcare providers.
- Expertise in neurology and oncology drug development.
- Global commercial infrastructure and distribution network.
What Does ESALY Do?
Eisai Co., Ltd., founded in 1941 in Japan, has evolved into a global pharmaceutical company with a focus on neurology, oncology, and global generic medicines. The company's mission is to prioritize patients and their families, aiming to increase the benefits healthcare provides to them. Eisai is dedicated to addressing unmet medical needs through innovative drug development and strategic collaborations. Its neurology portfolio includes treatments for Alzheimer's disease, epilepsy, and pain management. In oncology, Eisai focuses on developing therapies for various cancers, including liver cancer and soft tissue sarcoma. The company has a significant presence in Japan, the United States, Europe, and Asia, with research and development facilities and commercial operations in these regions. Eisai's commitment to research and development is evident in its pipeline of novel drug candidates, reflecting its focus on addressing critical healthcare challenges and improving patient outcomes worldwide.
What Products and Services Does ESALY Offer?
- Develop and market pharmaceutical products for neurology and oncology.
- Focus on addressing unmet medical needs in areas such as Alzheimer's disease, epilepsy, and cancer.
- Conduct research and development to discover novel drug candidates.
- Collaborate with other pharmaceutical companies and research institutions.
- Manufacture and distribute pharmaceutical products globally.
- Provide patient support programs and educational resources.
How Does ESALY Make Money?
- Develop, manufacture, and market proprietary pharmaceutical products.
- Generate revenue through sales of prescription drugs.
- Invest in research and development to discover new drug candidates.
- Collaborate with other companies to co-develop and co-market products.
What Industry Does ESALY Operate In?
The pharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. Eisai operates in the neurology and oncology segments, which are experiencing significant growth due to aging populations and increasing prevalence of chronic diseases. The market for Alzheimer's disease treatments is particularly large, with a growing demand for disease-modifying therapies. Eisai's collaboration with Biogen positions it favorably in this market, but it faces competition from other pharmaceutical companies developing similar treatments. The industry is also subject to pricing pressures and increasing scrutiny from regulatory agencies.
Who Are ESALY's Key Customers?
- Patients with neurological disorders, such as Alzheimer's disease and epilepsy.
- Patients with various types of cancer.
- Healthcare providers, including physicians, hospitals, and clinics.
- Pharmacies and distributors.
- Government healthcare agencies.
Company Profile
Eisai Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Haruo Naito. ESALY has traded publicly since 1995.
Eisai Co., Ltd. (ESALY) Valuation Context
Valued at $17.6B, ESALY is classified as a large-cap stock. Relative to its peer group, ESALY's quantitative score of 57/100 is roughly in line with the peer average of 63/100.
Key Financial Metrics
Return on equity for Eisai Co., Ltd. stands at 4.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.7%, showing how much profit it generates from its asset base. ESALY trades at a trailing price-to-earnings ratio of 30.04, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.24 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Eisai Co., Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.15 places it in the safe zone, indicating low near-term bankruptcy risk.
ESALY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Eisai has seen increased community enthusiasm surrounding its recent advancements in Alzheimer's research, reflecting a strong belief in its potential market impact.
- Recent insider buying suggests confidence among executives about the company's future direction and pipeline.
- Positive sentiment from healthcare professionals and analysts regarding Eisai's innovative drug developments has bolstered community support.
- The company's strategic partnerships with leading research institutions have enhanced its credibility and visibility in the biotech space.
Bear Case
- Concerns about regulatory hurdles for new drug approvals have dampened some investor enthusiasm, creating a cautious outlook.
- Recent market volatility has led to heightened skepticism among traders about the biotech sector's stability, affecting sentiment around Eisai.
- Community discussions indicate worries over competition from other firms in Alzheimer's treatment, which could dilute Eisai's market share.
- There have been mixed reviews on the effectiveness of Eisai's pipeline products, leading to uncertainty in investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
ESALY Latest News
No recent news available for ESALY.
ESALY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ESALY.
Price Targets
Wall Street price target analysis for ESALY.
ESALY MoonshotScore
What does this score mean?
The MoonshotScore rates ESALY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Eisai Co., Ltd. ADR Information Unsponsored
Eisai Co., Ltd. (ESALY) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: ESAL
ESALY OTC Market Information
ESALY trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
ESALY Healthcare Stock FAQ
What does the AI Score mean for ESALY?
ESALY holds an AI Score of 57/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Eisai Co., Ltd. is a Japan-based pharmaceutical company focused on neurology, oncology, and global generic medicines. The company aims to address unmet medical needs and improve the lives …
What does ESALY do?
Eisai Co., Ltd. is a global pharmaceutical company focused on neurology and oncology. The company develops and markets pharmaceutical products for the treatment of diseases such as Alzheimer's disease, epilepsy, and various cancers.
What do analysts say about ESALY stock?
Analyst consensus regarding ESALY stock is mixed, reflecting the inherent uncertainty of pharmaceutical drug development and regulatory approvals. Key valuation metrics include price-to-earnings ratio, price-to-sales ratio, and discounted cash flow analysis.
What are the main risks for ESALY?
The main risks for Eisai include regulatory setbacks and delays, unfavorable clinical trial outcomes, competition from other pharmaceutical companies, pricing pressures and healthcare reforms, and product liability claims and litigation. Regulatory risks involve the potential rejection of drug candidates by regulatory agencies, such as the FDA and EMA.
What are the key factors to evaluate for ESALY?
Eisai Co., Ltd. (ESALY) holds an AI score of 57/100 (moderate). P/E: 30.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does ESALY data refresh on this page?
ESALY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ESALY's recent stock price performance?
Eisai Co., Ltd. (ESALY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong pipeline of neurology and oncology drugs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ESALY overvalued or undervalued right now?
Eisai Co., Ltd. (ESALY) trades at 30.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ESALY before investing?
Before investing in Eisai Co., Ltd. (ESALY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data may be limited or delayed.